Peptide Library

In clinical trials

Heart & blood

Balixafortide

Evidence

Clinical trials

Class

CXCR4 antagonist peptide

/

Balixafortide

KEY TAKEAWAY

Balixafortide is a synthetic cyclic peptide that blocks the CXCR4 receptor. It has been studied for metastatic breast cancer alongside chemotherapy. Balixafortide is not FDA-approved. A phase 3 trial combined with eribulin did not meet its main goal.

Written by the Veylo editorial team · Updated

November 2026

At a glance

At a glance

What it is

CXCR4 antagonist peptide

Being studied for

Studied in metastatic breast cancer

Key fact

Balixafortide is not FDA-approved. A phase 3 trial combined with eribulin did not meet its main goal.

Route

Intravenous infusion in trials

Evidence strength

Clinical trials

What it is

What it is

Balixafortide is a synthetic cyclic peptide that blocks the CXCR4 receptor. It has been studied for metastatic breast cancer alongside chemotherapy.

How it works

How it works

Blocking CXCR4 may make tumors more vulnerable to chemotherapy and to immune attack.

Regulatory status

Regulatory status

Balixafortide is not FDA-approved. A phase 3 trial combined with eribulin did not meet its main goal.

What it is used for

What it is used for

Studied in metastatic breast cancer.

Side effects and risks

Side effects and risks

Infusion reactions and injection-related effects were reported in trials.

Citations

Citations

Balixafortide: see PubMed and ClinicalTrials.gov for published studies and registered trials. No FDA drug label exists for the uses described.

Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.

Veylo

Clinician-guided peptide care, paired with baseline blood testing and ongoing support.

Peptides referenced on this site are compounded medications and are investigational; they have not been approved by the FDA for the uses described. Nothing here is medical advice. Prescriptions are issued only after a licensed clinician reviews your history.

© 2026 Veylo. All rights reserved.

Veylo

Veylo

Veylo